New Anti-Obesity Medications Should Be Consider...

By Danélia Botes

August 6, 2024

Introduction Federal policymakers are evaluating a new class of drugs for managing and preventing type 2 diabetes symptoms. These medications, known as glucagon-like peptide-1 (GLP-1) receptor agonists, have shown unexpected success in w...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.